Providence Portland Medical Center

2320.8 miles away
503-215-1111

Providence Portland Medical Center

Providence Portland Medical Center is a Magnet®-Designated Hospital, the highest credential for nursing facilities in the U.S. and around the world.

As part of Providence Health & Services in Oregon, we're a not-for-profit network of hospitals, health plans, physicians, clinics and affiliated health services. We are recognized for excellence in patient care and research in areas such as cancer, heart, orthopedics, women's health, rehabilitation services and behavioral health.

Learn More About Us

Providence Portland Medical Center Foundation is the philanthropic arm of the hospital, dedicated to enhancing quality health care at Providence Portland Medical Center and the communities it serves. Donations large and small make a difference in the lives of those cared for by Providence Portland Medical Center.

Your gift allows us to provide compassionate care for all who come to us, regardless of their ability to pay. Your gift gives hope. Your support provides research for life-saving treatments and the purchase of equipment. Our ability to achieve excellence relies heavily on the generosity of donors like you and our volunteers.

Make a Donation

News & Information From Our Experts

Get the latest news, important information and updates from our experts.

9/22/2023
Providence Cancer Institute of Oregon announces new division director and deputy director of Hematology and Medical Oncology.
9/18/2023
For Gynecologic Cancer Awareness Month, Providence Cancer Institute highlights a clinical trial that evaluates the safety and effectiveness of a new oral treatment for grade 1 endometrial cancer.
7/27/2023
In 2021, Dr. Nicole Schmidt was driving around a curve when she saw a car headed straight for her. The crash sent her to a trauma center and started a journey of healing, learning and becoming.
7/10/2023
A phase II trial tests FOLFOX or CAPOX versus FOLFIRINOX in patients with locally advanced rectal cancer, and a phase I trial evaluates TBio-4101 in patients with advanced solid tumors.